This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Nov 28;386(10009):2143.

doi: 10.1016/S0140-6736(15)01052-1.

Primary chemotherapy versus primary surgery for ovarian cancer - Authors' reply

Sean Kehoe¹, Matthew Nankivell²

Affiliations

Affiliations

¹ School of Cancer Sciences, University of Birmingham, Birmingham, UK.
² Medical Research Council Clinical Trials Unit, University College London, London WC2B 6NH, UK. Electronic address: m.nankivell@ucl.ac.uk.

PMID: 26638963
DOI: 10.1016/S0140-6736(15)01052-1

Comment

Primary chemotherapy versus primary surgery for ovarian cancer - Authors' reply

Sean Kehoe et al. Lancet. 2015.

. 2015 Nov 28;386(10009):2143.

doi: 10.1016/S0140-6736(15)01052-1.

Authors

Sean Kehoe¹, Matthew Nankivell²

Affiliations

¹ School of Cancer Sciences, University of Birmingham, Birmingham, UK.
² Medical Research Council Clinical Trials Unit, University College London, London WC2B 6NH, UK. Electronic address: m.nankivell@ucl.ac.uk.

PMID: 26638963
DOI: 10.1016/S0140-6736(15)01052-1

No abstract available

PubMed Disclaimer

Comment on

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Kehoe S, et al. Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19. Lancet. 2015. PMID: 26002111 Clinical Trial.
Primary chemotherapy versus primary surgery for ovarian cancer.
Gasparri ML, Panici PB, Papadia A. Gasparri ML, et al. Lancet. 2015 Nov 28;386(10009):2142-3. doi: 10.1016/S0140-6736(15)01051-X. Lancet. 2015. PMID: 26638961 No abstract available.
Primary chemotherapy versus primary surgery for ovarian cancer.
Scaletta G, Plotti F, Aloisi A, Angioli R. Scaletta G, et al. Lancet. 2015 Nov 28;386(10009):2142. doi: 10.1016/S0140-6736(15)01050-8. Lancet. 2015. PMID: 26638962 No abstract available.

Similar articles

Primary chemotherapy versus primary surgery for ovarian cancer.
Scaletta G, Plotti F, Aloisi A, Angioli R. Scaletta G, et al. Lancet. 2015 Nov 28;386(10009):2142. doi: 10.1016/S0140-6736(15)01050-8. Lancet. 2015. PMID: 26638962 No abstract available.
Primary chemotherapy versus primary surgery for ovarian cancer.
Gasparri ML, Panici PB, Papadia A. Gasparri ML, et al. Lancet. 2015 Nov 28;386(10009):2142-3. doi: 10.1016/S0140-6736(15)01051-X. Lancet. 2015. PMID: 26638961 No abstract available.
Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply.
Pignata S, Di Maio M, Gallo C, Perrone F. Pignata S, et al. Lancet Oncol. 2014 Jun;15(7):e250-1. doi: 10.1016/S1470-2045(14)70219-0. Lancet Oncol. 2014. PMID: 24872107 No abstract available.
[Ovarian cancer from the standpoint of medical oncology].
Kato Y, Katsumata N. Kato Y, et al. Gan To Kagaku Ryoho. 2007 Jul;34(7):1017-21. Gan To Kagaku Ryoho. 2007. PMID: 17637538 Review. Japanese.
Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer.
Kitchener HC. Kitchener HC. Cancer Treat Rev. 2005 Jun;31(4):323-7. doi: 10.1016/j.ctrv.2005.04.003. Cancer Treat Rev. 2005. PMID: 15905036 Review. No abstract available.

See all similar articles

Cited by

Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.
Di Lorenzo G, Ricci G, Severini GM, Romano F, Biffi S. Di Lorenzo G, et al. Theranostics. 2018 Jul 30;8(16):4279-4294. doi: 10.7150/thno.26345. eCollection 2018. Theranostics. 2018. PMID: 30214620 Free PMC article. Review.
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Torres D, Hou X, Bale L, Heinzen EP, Maurer MJ, Zanfagnin V, Oberg AL, Conover C, Weroha SJ. Torres D, et al. PLoS One. 2019 Nov 21;14(11):e0224564. doi: 10.1371/journal.pone.0224564. eCollection 2019. PLoS One. 2019. PMID: 31751381 Free PMC article.
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS. Sioulas VD, et al. Gynecol Oncol. 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. Epub 2017 Feb 21. Gynecol Oncol. 2017. PMID: 28238354 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information